Content of review 1, reviewed on September 04, 2020

This is a very shameful paper which is published by the leading Journal. The major point of the paper is safety. This vaccine today is already distributed inside Russia. The majority of patients have had hyperthermia, headache, and so on. Scientifically speaking the authors published a very politically-promoted paper with a plethora of side effects out of stage 3 of the clinical trials. Meanwhile, this vaccine is registered in Russia and spread for the needs of the army, physicians, and teachers. I would condemn this decision of Lancet to publish such a trial merely because this research group violated the principles of ethics under the supervision of the Russian government. The implementation of this vaccine into real clinical practice prior to initiation of the 3rd phase is a reason to reject such a paper up-front. This is a malpractice of the Russian pseudo-science. The vaccine is not tested enough especially in the sense of safety. Unfortunately, the editors of Lancet did not pay enough attention to this option.

Source

    © 2020 the Reviewer (CC BY 4.0).

References

    Y., L. D., V., D. I., V., Z. O., I., T. A., V., S. D., S., D. A., M., G. D., S., E. A., V., K. A., G., B. A., M., I. F., Olga, P., A., O. T., B., E. I., A., F. I., I., Z. D., V., V. D., N., S. D., S., S. A., V., S. Y., A., T. E., L., L. N., A., E. D., M., S. M., A., N. N., F., M. L., A., S. E., V., K. E., F., B. V., V., B. S., S., N. B., L., G. A. 2020. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet.